

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
August 6, 2008
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, August 6, 2008.

2. Welcome

Debbie Tapley, R.Ph. called the meeting to order and welcomed members, guests, and staff members.

Debbie Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

Debbie Tapley congratulated Dr. Kelly Jones, Pharm.D. on his recent election as President of the South Carolina Pharmacy Association.

3. Committee Members Present:

Ed Behling, M.D.

Greg Browning, M.D.

Joe Horvath, M.D.

Kelly Jones, Pharm.D.

Jim Lindsay, M.D.

Sara Lindsey, M.D.

Thomas Phillips, R.Ph.

Tan Platt, M.D.

Charles Raine, M..D.

Debbie Tapley, R.Ph.

George E. Vess, Pharm. D.

Harry Wright, M.D.

DHHS Staff Present:

Emma Forkner, Medicaid Director

Marion Burton, M.D.

James M Assey, R.Ph.

Mike Blakely, R.Ph.

Deidra Singleton, J.D.

Jim Bradford, M.D.

Other Representation:

First Health Services. – Mary Roberts, R.Ph.

Pharmaceutical Industry Speakers

Senator Jake Knotts

Representative Leon Howard

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, May 7, 2008.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

The rules for public comment were outlined. Debbie Tapley instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

| Company | Speaker | Drug |
|---------------------------------------|----------------------------|------------|
| Schering Plough | Adam Shprecher, Pharm.D. | Avelox® |
| Ortho-McNeal, Janssen Pharmaceuticals | Ying Cheung Yee, Ph.D. | Levaquin® |
| Schering Plough | John Howard, Pharm.D. | Nasonex® |
| Glaxo Smith Kline | Phil Cates, Pharm.D.. | Veramyst® |
| Sanofi Aventis | Jeffrey G. Harless, Ph.D. | Ambien CR® |
| Takeda Pharmaceuticals | Shalini Hede, Pharm.D. | Rozerem® |
| Allergen | Kenneth B. Mitchell, M.D. | Lumigan® |
| Amgen | Ann Lyons, Pharm.D.,BCPS | Epogen® |
| Stiefel | Michelle Welch, M.D. | Duac CS® |
| Sanofi Aventis | Rahsonda Burkett, Pharm.D. | Plavix® |

C. Drug Classes for Review

Mary Roberts, R.Ph., First Health Services Corporation, led the discussion for the following drug classes:

- Oral Quinolones
- Long Acting Narcotics
- Nasal Steroids
- Sedative/Hypnotics
- Ophthalmic Prostaglandins
- Hematopoietics
- Platelet Inhibitors
- Benzoyl Peroxide/Clindamycin Combination Products

The chart below represents the recommendations from the P & T Committee:

Oral Quinolones

| NO PA REQUIRED "PREFERRED" | PA REQUIRED |
|---|---|
| AVELOX® AVELOX ABC PACK® CIPROFLOXACIN OFLOXACIN | CIPRO® CIPRO ER® CIPROFLOXACIN ER FACTIVE® LEVAQUIN® NOROXIN® PROQUIN XR® |

An educational statement should be added to the posting addressing the risk associated with Avelox® use in Pyelonephritis.

Long Acting Narcotics

| NO PA REQUIRED "PREFERRED" | PA REQUIRED |
|--|--|
| DURAGESIC® KADIAN® MORPHINE SULFATE ER | AVINZA® FENTANYL PATCH MS CONTIN® OPANA ER® ORAMORPH SR® OXYCONTIN® OXYCODONE ER |

Patients 65 years or older or with a diagnosis of sickle cell anemia qualify for approval of PA request for Oxycontin®.

Nasal Steroids

| NO PA REQUIRED "PREFERRED" | PA REQUIRED |
|------------------------------------|---|
| FLUTICASONE PROPIONATE NASONEX® | BECONASE AQ® FLONASE® FLUNISOLIDE NASACORT AQ® RHINOCORT AQUA® VERAMYST® |

Sedative/Hypnotics

| NO PA REQUIRED "PREFERRED" | PA REQUIRED |
|-----------------------------------|--|
| TEMAZEPAM ZOLPIDEM | AMBIEN® AMBIEN CR® DORAL® ESTAZOLAM FLURAZEPAM HALCION® LUNESTA® RESTORIL® ROZEREM® SOMNOTE® TRIAZOLAM |

Ophthalmic Prostaglandins

| NO PA REQUIRED "PREFERRED" | PA REQUIRED |
|--|--------------------|
| LUMIGAN® TRAVATAN® TRAVATAN Z® XALATAN® | |

| <i>Hematopoietics</i> | |
|----------------------------|-------------|
| NO PA REQUIRED "PREFERRED" | PA REQUIRED |
| ARANESP® PROCRIPT® | EPOGEN® |

| <i>Benzoyl Peroxide/Clindamycin Combination Products</i> | |
|--|-------------|
| NO PA REQUIRED "PREFERRED" | PA REQUIRED |
| BENZACLIN® DUAC® DUAC CS® | |

| <i>Platelet Inhibitors</i> | |
|----------------------------|--|
| NO PA REQUIRED "PREFERRED" | PA REQUIRED |
| AGGRENOX® PLAVIX® | TICLID® DIPYRIDAMOLE TICLODIPINE |

5. **Old Business**

6. **New Business**

Debbie Tapley announced the classes for review at the August Meeting:

- Immunosuppressants*
- Insulin Mix*
- Cholinesterase Inhibitors*
- Andronergic Agents*
- Calcitonins*
- Androgen Hormone Inhibitors*
- NK1 Antagonist*
- NMDA Receptor Antagonist*
- Hepatitis B Therapy*
- Long Acting Beta Adrenergic Nebulizers*
- Ophthalmic Macrolides*
- Nitroimidazoles*

The committee requested data indicating patients 10 years and under who receive refills on their nasal steroids and for patients with history of diabetes and use of glaucoma medications. Mary Roberts will provide this information at the November meeting.

Senator Jake Knotts and Representative Leon Howard addressed the committee members and thanked them for their service. Both had questions regarding the P&T process and engaged the committee in discussion. A letter containing specific questions was presented to Director Forkner and the committee members at the end of the discussion. The Agency and the committee will work together to answer the questions and will return the answers to Senator Knotts and Representative Howard.

The committee agreed that it would be appropriate to post all antipsychotic agents as preferred to enable SC DHHS to invoice for supplemental rebate.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

- Oral Quinolones
- Long Acting Narcotics
- Nasal Steroids
- Sedative Hypnotics
- Ophthalmic Prostaglandin Agonists
- Hematopoietics
- Benzoyl Peroxide/Clindamycin Combinations
- Platelet Inhibitors

8. **Closing Comments**

The next meeting will be held on Wednesday, November 5, 2008 at 4:00 p.m. at the same location.

9. **Adjournment**

The meeting adjourned at 7:05p.m.